Skip to main content

Advertisement

SpringerLink
Log in

Donor-Transmitted Melanoma: Is It Still Bothering Us?

  • Skin Cancer (T Ito, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Global organ scarcity remains a severe obstacle because of the rapid growth in the number of patients on the transplant waiting list. Transplant centres strive to raise the number of donors by proposing more mild criteria for donor selection, among them donors with a history of malignancy and older age. Recipients are at hazard of acquiring tumour that existed in the donor at the time of transplantation with the most common cancers been renal cell carcinoma (57%), melanoma (10%), and choriocarcinoma (9%). Tumour origin can be established by PCR-based DNA analysis for microsatellite markers, HLA typing, immunohistochemistry, or fluorescent in situ hybridisation. The general recommendation for treatment of donor-related melanoma is a cessation of immunosuppression therapy to allow rejection of the allograft and its immediate removal. In non-renal transplant patients with life-sustaining organs or if allograft removal is denied, reduction of immunosuppression, chemoradiation therapy, and urgent retransplantation are the only potential strategies. Checkpoint inhibitors were reported to be effective in several cases of donor-transmitted melanoma and now emerge as an innovative option to standard chemotherapy and the potential for cure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Abouna G. Organ shortage crisis: problems and possible solutions. Transplant Proc. 2008;40:34–8.

    Article  CAS  Google Scholar 

  2. Chang GJ, Mahanty HD, Ascher NL, Roberts JP. Expanding the donor pool: can the Spanish model work in the United States? Am J Transplant. 2003;3:1259–63.33.

    Article  Google Scholar 

  3. Extermann M. Interaction between comorbidity and cancer. Cancer Control. 2007;14:13–22.

    Article  Google Scholar 

  4. The Organ Procurement and Transplantation Network database. Https://optn.transplant.hrsa.gov/data/view-data-reports/build-advanced/ (accessed Dec 7, 2019).

  5. Friedman CF, Wolchok JD. Checkpoint inhibition and melanoma: Considerations in treating the older adult. J Geriatr Oncol. 2017;8:237–41.

    Article  Google Scholar 

  6. Gandhi MJ, Strong DM. Donor derived malignancy following transplantation: a review. Cell Tissue Bank. 2007;8:267–86.

    Article  Google Scholar 

  7. Kauffman HM, Mcbride MA, Cherikh WS, Spain PC, Hanto DW, Delmonico FL. Donor-related malignancies. Transplant Rev. 2002;16:177–91.

    Article  Google Scholar 

  8. Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 2014;28:1005–11.

    PubMed  Google Scholar 

  9. Strauss DC, Thomas JM. Transmission of donor melanoma by organ transplantation. Lancet Oncol. 2010;11:790–6.

    Article  Google Scholar 

  10. Bilal M, Eason JD, Das K, Sylvestre PB, Dean AG, Vanatta JM. Donor-derived metastatic melanoma in a liver transplant recipient established by DNA fingerprinting. Exp Clin Transplant. 2013;11:458–63.

    Article  Google Scholar 

  11. Kim JK, Carmody IC, Cohen AJ, Loss GE. Donor transmission of malignant melanoma to a liver graft recipient: case report and literature review. Clin Transpl. 2009;23:571–4.

    Article  Google Scholar 

  12. Bajaj NS, Watt C, Hadjiliadis D, et al. Donor transmission of malignant melanoma in a lung transplant recipient 32 years after curative resection. Transpl Int. 2010;23:e26–31.

    Article  Google Scholar 

  13. Chen KT, Olszanski A, Farma JM. Donor transmission of melanoma following renal transplant. Case Rep Transplant. 2012;2012:1–3.

    Google Scholar 

  14. • Singh P, Pandey D, Rovin B, Pesavento TE, Olencki T. Successful treatment and five years of disease-free survival in a donor transmitted metastatic melanoma with ipilimumab therapy. Cureus. 2019;11:e4658 A case report showing ipilimumab advantages in the treatment of donor-transmitted melanoma.

    PubMed  PubMed Central  Google Scholar 

  15. Boyle S, Ali N, Olszanski A, Park D, Xiao G, Guy S, et al. Donor-derived metastatic melanoma and checkpoint inhibition. Transplant Proc. 2017;49:1551–4.

    Article  CAS  Google Scholar 

  16. • Alsara A, Rafi M. Donor-transmitted melanoma after limbal stem cell transplantation. Avicenna J Med. 2017;7:75–7 A case report indicating the first case of melanoma transmission after a limbal stem cell transplant. After this case, the Eye Bank Association of America reviewed the criteria for ocular tissue transplantation and excluded donors of ocular tissue with any history of melanoma.

    Article  Google Scholar 

  17. Sepsakos L, Cheung AY, Nerad JA, Mogilishetty G, Holland EJ. Donor-derived conjunctival-limbal melanoma after a keratolimbal allograft. Cornea. 2017;36:1415–8.

    Article  Google Scholar 

  18. Kriegshauser JS, Weidenfeld PL, Wochos DN, Williams JW. Auto-rejection of renal donor-origin metastatic melanoma. Radiol Case Rep. 2006;1:149–53.

    Article  Google Scholar 

  19. Patel PM, Suciu S, Mortier L, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomized phase III study (EORTC 18032). Eur J Cancer. 2011;47:1476–83.

    Article  CAS  Google Scholar 

  20. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology. 2009;23:488–96.

    PubMed  Google Scholar 

  21. Lui P, Cashin R, Machado M, et al. Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev. 2007;33:665–80.

    Article  Google Scholar 

  22. Yung WK. Temozolomide in malignant gliomas. Semin Oncol. 2000;27:27–34.

    CAS  PubMed  Google Scholar 

  23. Wick W, Platten M, Weller M. New (alternative) temozolomide regimens for the treatment of glioma. Neuro-Oncology. 2009;11:69–79.

    Article  CAS  Google Scholar 

  24. Yung WK, Albright RE, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588–93.

    Article  CAS  Google Scholar 

  25. Agarwala SS, Kirkwood JM, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol. 2004;22:2101–7.

    Article  CAS  Google Scholar 

  26. Bleehen NM, Newlands ES, et al. Cancer research campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol. 1995;13:910–3.

    Article  CAS  Google Scholar 

  27. Mian R, Henderson MA, et al. Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion. Can J Surg. 2001;44:189–92.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Hersh EM, O’Day SJ, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Investig New Drugs. 2011;29:489–98.

    Article  CAS  Google Scholar 

  29. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745–51.

    Article  CAS  Google Scholar 

  30. Wilson MA, Schuchter LM. Chemotherapy for melanoma. New York: Springer; 2016. p. 209–29.

    Book  Google Scholar 

  31. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.

    Article  CAS  Google Scholar 

  32. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAFV600E andBRAFV600Kmutation-positivemelanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15:323–32.

    Article  CAS  Google Scholar 

  33. •• Bomar L, Senithilnathan A, Ahn C. Systemic therapies for advanced melanoma. Dermatologic Clinics. 2019;37(4):409–23 A review article showing the most recent and beneficial treatment options for advanced melanoma.

    Article  CAS  Google Scholar 

  34. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600–mutant advanced melanoma treated with Vemurafenib. N Engl J Med. 2012;366:707–14.

    Article  CAS  Google Scholar 

  35. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF mutated melanoma. NEngl JMed. 2012;367:107–14.

    Article  CAS  Google Scholar 

  36. Hodi FS, O’DAY SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.

    Article  CAS  Google Scholar 

  37. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889–94.

    Article  CAS  Google Scholar 

  38. Kwong A, Sanlorenzo M, Rappersberger K, Vujic I. Update on advanced melanoma treatments: small molecule targeted therapy, immunotherapy, and future combination therapies. Wien Med Wochenschr. 2017;169:314–22.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kazakh National Medical University named after S.D. Asfendiyarov, 94 Tole Bi Street, Almaty, Kazakhstan

    Leila Abdullayeva Dr

Authors
  1. Leila Abdullayeva Dr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leila Abdullayeva Dr.

Ethics declarations

Conflict of Interest

Leila Abdullayeva declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Skin Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abdullayeva, L. Donor-Transmitted Melanoma: Is It Still Bothering Us?. Curr. Treat. Options in Oncol. 21, 38 (2020). https://doi.org/10.1007/s11864-020-00740-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-020-00740-0

Keywords

Search

Navigation